Skip to main content

P Sharma

First name:
P
Last name:
Sharma
Tyagi, A. ., Sandhya, S. ., Sharma, P. ., Saxena, S. ., Sharma, R. ., Mithra, S. A., … Gaikwad, K. . (2019). The genome size of clusterbean (Cyamopsis tetragonoloba) is significantly smaller compared to its wild relatives as estimated by flow cytometry. Gene. https://doi.org/10.1016/j.gene.2019.02.090 (Original work published 2019)
Haymaker, C. ., Kim, D. ., Uemura, M. ., Vence, L. ., Phillip, A. ., McQuail, N. ., … Diab, A. . (2017). Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunology Research, 5(2), 100-105. https://doi.org/10.1158/2326-6066.CIR-16-0223
Zamarin, D. ., Holmgaard, R. ., Ricca, J. ., Plitt, T. ., Palese, P. ., Sharma, P. ., … Allison, J. . (2017). Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications, 8, 14340. https://doi.org/10.1038/ncomms14340 (Original work published 2017)
Morris, V. ., Salem, M. ., Nimeiri, H. ., Iqbal, S. ., Singh, P. ., Ciombor, K. ., … Eng, C. . (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 18(4), 446-453. https://doi.org/10.1016/S1470-2045(17)30104-3
Bennett, C. ., Vakil, N. ., Bergman, J. ., Harrison, R. ., Odze, R. ., Vieth, M. ., … Jankowski, J. . (2012). Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology, 143(2), 336-46. https://doi.org/10.1053/j.gastro.2012.04.032
Gao, J. ., Ward, J. ., Pettaway, C. ., Shi, L. ., Subudhi, S. ., Vence, L. ., … Sharma, P. . (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308
Reilley, M. ., Bailey, A. ., , Janku, F. ., Naing, A. ., Falchook, G. ., … Hong, D. . Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. Journal for Immunotherapy of Cancer, 5, 35. https://doi.org/10.1186/s40425-017-0238-1 (Original work published 2017)
Boddu, P. ., Kantarjian, H. ., Garcia-Manero, G. ., Allison, J. ., Sharma, P. ., & Daver, N. . (2018). The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia & Lymphoma, 59(4), 790-802. https://doi.org/10.1080/10428194.2017.1344905
Reuben, A. ., Gittelman, R. ., Gao, J. ., Zhang, J. ., Yusko, E. ., Wu, C. ., … Zhang, J. . (2017). TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 7(10), 1088-1097. https://doi.org/10.1158/2159-8290.CD-17-0256
Wei, S. ., Levine, J. ., Cogdill, A. ., Zhao, Y. ., Anang, N. ., Andrews, M. ., … Allison, J. . (2017). Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, 170(6), 1120-1133.e17. https://doi.org/10.1016/j.cell.2017.07.024 (Original work published 2017)